ThromboGenics and VIB form new oncology company for pediatric brain tumors

14 April 2015

Ophthalmic specialist biopharma company ThromboGenics (Euronext Brussels: THR) has founded Oncurious, a new oncology company that will develop TB-403 for the treatment of pediatric brain tumors.

VIB, a Belgium-based life sciences institute, will become a shareholder alongside ThromboGenics. TB-403 is a humanized monoclonal antibody against placental growth factor (PlGF). PlGF is expressed in several types of cancer, including medulloblastoma, a rare, life-threatening brain tumor that mainly affects children. High expression of the PlGF receptor neuropilin 1 has been shown to correlate with poor overall survival.

Treatment with TB-403 in relevant animal models for medulloblastoma has demonstrated beneficial effects on tumor growth and survival. Oncurious now plans to start a Phase I/IIa program with TB-403 in medulloblastoma patients, with enrolment of the first patient expected for the end of 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK